Limits...
A Novel Point-of-Care BioNanoSensor for Rapid HIV Detection and Treatment Monitoring.

Rozmyslowicz T, deSa J, Lec R, Gaulton GN - J AIDS Clin Res (2015)

Bottom Line: The detection range of the BNS device for the biomarker gp120 displayed a low-end sensitivity of 6.5×10(4) HIV viral particles/ml, while using a small fluid sample (5 µl) and with a reaction time of less then 30 seconds.Performance of this device indicated that the BNS has utility for direct detection of HIV particles prior to, and independent from, antibody formation.The BNS parameters of small sample volume, compact device size, and detection sensitivity indicate that the BNS is potentially useful in the point-of-care and/or home setting for monitoring decisions regarding HIV treatment on a real-time basis.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia, USA.

ABSTRACT

We report here a new diagnostic approach to the direct detection of HIV in blood or other body fluids that is rapid, sensitive and potentially applicable in a point-of-care setting. The approach follows on the development of a novel BioNanoSensor (BNS) device that utilizes piezoelectric technology to detect the presence of the HIV surface glycoprotein gp120 in a nanoscale format. The detection range of the BNS device for the biomarker gp120 displayed a low-end sensitivity of 6.5×10(4) HIV viral particles/ml, while using a small fluid sample (5 µl) and with a reaction time of less then 30 seconds. Performance of this device indicated that the BNS has utility for direct detection of HIV particles prior to, and independent from, antibody formation. Accordingly, this device holds utility to monitor the status of HIV infection both early after exposure to virus as well as during chronic HIV infection. The BNS parameters of small sample volume, compact device size, and detection sensitivity indicate that the BNS is potentially useful in the point-of-care and/or home setting for monitoring decisions regarding HIV treatment on a real-time basis.

No MeSH data available.


Related in: MedlinePlus

BNS resonant frequency change in response to HIV-1 in human plasma: Plasma samples were obtained from 10 seropositive individuals and the BNS response measured using a sensor loaded with either (A) blocked by addition of BSA/no antibody or (B) anti-gp120. Histograms represent the sensor response inflection at 200MHz.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4596080&req=5

Figure 4: BNS resonant frequency change in response to HIV-1 in human plasma: Plasma samples were obtained from 10 seropositive individuals and the BNS response measured using a sensor loaded with either (A) blocked by addition of BSA/no antibody or (B) anti-gp120. Histograms represent the sensor response inflection at 200MHz.

Mentions: With knowledge of both BNS binding specificity and sensitivity to gp120 in hand, we extended our analysis to the direct detection of HIV-1 in plasma samples obtained from individuals infected with HIV-1. So that these experiments might be conducted without unnecessary health risks, samples were first rendered replication defective by heat treatment. The BNS frequency change in samples from HIV-1 seropositive individuals, as contrasted to control, is shown in Figure 4. For this analysis, plasma aliquots obtained from ten seropositive individuals were analyzed in parallel using the BNS device in either the presence or absence of detecting anti-gp120 antibody. The virus load of these samples ranged from 0.14–1.6×106 copies/ml.


A Novel Point-of-Care BioNanoSensor for Rapid HIV Detection and Treatment Monitoring.

Rozmyslowicz T, deSa J, Lec R, Gaulton GN - J AIDS Clin Res (2015)

BNS resonant frequency change in response to HIV-1 in human plasma: Plasma samples were obtained from 10 seropositive individuals and the BNS response measured using a sensor loaded with either (A) blocked by addition of BSA/no antibody or (B) anti-gp120. Histograms represent the sensor response inflection at 200MHz.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4596080&req=5

Figure 4: BNS resonant frequency change in response to HIV-1 in human plasma: Plasma samples were obtained from 10 seropositive individuals and the BNS response measured using a sensor loaded with either (A) blocked by addition of BSA/no antibody or (B) anti-gp120. Histograms represent the sensor response inflection at 200MHz.
Mentions: With knowledge of both BNS binding specificity and sensitivity to gp120 in hand, we extended our analysis to the direct detection of HIV-1 in plasma samples obtained from individuals infected with HIV-1. So that these experiments might be conducted without unnecessary health risks, samples were first rendered replication defective by heat treatment. The BNS frequency change in samples from HIV-1 seropositive individuals, as contrasted to control, is shown in Figure 4. For this analysis, plasma aliquots obtained from ten seropositive individuals were analyzed in parallel using the BNS device in either the presence or absence of detecting anti-gp120 antibody. The virus load of these samples ranged from 0.14–1.6×106 copies/ml.

Bottom Line: The detection range of the BNS device for the biomarker gp120 displayed a low-end sensitivity of 6.5×10(4) HIV viral particles/ml, while using a small fluid sample (5 µl) and with a reaction time of less then 30 seconds.Performance of this device indicated that the BNS has utility for direct detection of HIV particles prior to, and independent from, antibody formation.The BNS parameters of small sample volume, compact device size, and detection sensitivity indicate that the BNS is potentially useful in the point-of-care and/or home setting for monitoring decisions regarding HIV treatment on a real-time basis.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia, USA.

ABSTRACT

We report here a new diagnostic approach to the direct detection of HIV in blood or other body fluids that is rapid, sensitive and potentially applicable in a point-of-care setting. The approach follows on the development of a novel BioNanoSensor (BNS) device that utilizes piezoelectric technology to detect the presence of the HIV surface glycoprotein gp120 in a nanoscale format. The detection range of the BNS device for the biomarker gp120 displayed a low-end sensitivity of 6.5×10(4) HIV viral particles/ml, while using a small fluid sample (5 µl) and with a reaction time of less then 30 seconds. Performance of this device indicated that the BNS has utility for direct detection of HIV particles prior to, and independent from, antibody formation. Accordingly, this device holds utility to monitor the status of HIV infection both early after exposure to virus as well as during chronic HIV infection. The BNS parameters of small sample volume, compact device size, and detection sensitivity indicate that the BNS is potentially useful in the point-of-care and/or home setting for monitoring decisions regarding HIV treatment on a real-time basis.

No MeSH data available.


Related in: MedlinePlus